UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

 Date of Report (Date of earliest event reported): July 3, 2007 (June 27, 2007)

                                 Gene Logic Inc.

               (Exact Name of Registrant as Specified in Charter)


          Delaware                   0-23317                   06-1411336
(State or other jurisdiction   (Commission File Number)      (IRS Employer
        of incorporation)                                  Identification No.)

        50 West Watkins Mill Road, Gaithersburg, Maryland        20878
             (Address of principal executive office)           (Zip Code)

        Registrant's telephone number, including area code: (301) 987-1700

                                       N/A
          (Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions (see General Instruction A.2. below):


[_]  Written communication pursuant to Rule 425 under the Securities Act (17 CFR
     230.425)

[_]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
     240.14a-12)


[_]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
     Exchange Act (17 CFR 240.14d-2(b))

[_]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
     Exchange Act (17 CFR 240.135-4(c))

Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB control number.




Item 5.02 Departure of Directors or Principal Officers; Election of Directors;
          Appointment of Certain Officers; Compensatory Arrangements of Certain
          Officers.

1. Dr. Joanne Smith-Farrell, the Company's Senior Vice President of Business
Development and Licensing, resigned. The resignation will be effective as of
July 31, 2007.

                                       2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


                                                    GENE LOGIC INC.

Date: July 3, 2007                              By:  /s/ Philip L. Rohrer Jr.
                                                    -------------------------
                                                    Philip L. Rohrer Jr.
                                                    Chief Financial Officer

                                       3